DDN’s Post

How is AI currently reshaping the pharmaceutical landscape?     Some of the ways AI is making an impact are:  • Enhanced drug target identification: AI algorithms can analyse vast datasets to identify novel drug targets with greater accuracy and efficiency.  • Streamlined pre-clinical testing: AI can be used to design and conduct virtual experiments, reducing the need for animal testing and accelerating the development process.     AI plays a key role when developing effective discovery computational models, and our data team has identified 50+ pre-clinical CROs that offer computational chemistry and bioinformatics services.     Stay tuned for our featured companies within the space, including Luo Automation, one of our Disruptor Watchlist “Start Ups to watch”. 📈    #AIinPharma #Pharma #AIDrugDiscovery #ComputationalChemistry 

𝐌𝐞𝐧𝐭𝐞𝐧 𝐀𝐈 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 𝐨𝐧 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐌𝐚𝐜𝐫𝐨𝐜𝐲𝐜𝐥𝐞 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 Menten AI, Inc. Menten AI, a biotechnology company specializing in generative AI for peptide macrocycle design, announced a research collaboration and licensing agreement with Bristol Myers Squibb Bristol Myers Squibb. Menten AI’s platform uses machine learning, physics-based models, and quantum chemistry to optimize peptide macrocycles, reducing the number of candidate molecules needed for testing and iterations required to achieve drug-like properties. Through this collaboration, Menten AI and Bristol Myers Squibb Bristol Myers Squibb optimized the biochemical properties of certain peptide macrocycles, identifying new amino acid modifications. “This is a key milestone for Menten AI, demonstrating the maturity of our platform and generative AI to accelerate the discovery and optimization of next-generation peptide macrocycles,” noted Hans Melo Hans Melo, co-founder and CEO of Menten AI. #Biotech #AI #Pharma #DrugDiscovery #PeptideResearch #MachineLearning #HealthcareInnovation #Pharmaceuticals #GenerativeAI #ResearchCollaboration #MedicalResearch #Innovation #QuantumChemistry

#AI_in_Pharma_and_Biotech Market In-depth Analysis Report by Size, Share, Regional Analysis and Global Forecast to 2032. >> https://lnkd.in/dBUiqhAz AI in #pharma and biotech uses artificial #intelligence to enhance various aspects of #drug discovery, development, and #manufacturing. AI algorithms analyze vast #datasets to identify potential drug #candidates, predict #clinical trial outcomes, and optimize #production processes. This #technology accelerates research #timelines, reduces costs, and increases the accuracy of #predictive models. BenevolentAI Insilico Medicine Recursion Atomwise Cloud Pharmaceuticals, Inc. Deep Genomics Exscientia Schrödinger #healthcareindustry #pharmaceuticalindustry #healthcareresearch #biotechnology #artificialintelligence #manufacturing #clinicaltrial #biotech 

AI can be used in all aspects of drug development – from discovering biological targets, through developing chemical compounds, to conducting clinical trials. As we expected, this year at JP Morgan's Healthcare Conference, the AI theme was pervasive in almost every presentation, with key players presenting impressive new capabilities relevant to every stage of the value chain. Where does CytoReason fit into this growing trend? We use AI to model disease biology and drug effects. Our Computational Disease Models enable data integration across-the-board for decision making. The main goal is to help pharma enterprises improve probability of phase 2 success. Link to articles in comment below👇 #pharma #computationalbiology #biotech #drugdevelopment #jpm2024

There’s a real need for speed. While mass spec has traditionally thrived in centralized labs, we bring our technology directly to the point of need for rapid chemical analysis. Our CEO and Co-founder, Kevin J. Knopp, recently joined Nicole Raleigh at pharmaphorum to discuss this and other technological advancements, such as #AI and machine learning, that enables our biopharma customers to bring new #therapies and medicines to market faster. Check it out here: https://lnkd.in/eUmwY5e5

#Artificial_Intelligence_in_Drug_Screening Market - Upcoming Business Future Growth and Forecast To 2030. >> https://lnkd.in/dxrjWU5G The major factor driving the #artificial #intelligence #in #drug #screening #market #growth includes an increase in alchol consumption worldwide, a rise in the use of #narcotics and #illicit #drugs across the #globe, stringent government laws for drug screening, a rise in the adoption of #AI #systems, and #technological innovations in the field of drug screening. IBM Microsoft Atomwise Deep Genomics Cloud Pharmaceuticals, Inc. Insilico Medicine BenevolentAI Exscientia Cyclica BioAge Labs #Artificial_Intelligence_in_Drug_Screening #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #artificial #intelligence #in #drug #screening

https://lnkd.in/gf5SWDzA Watch on demand as we unveil the transformative impacts of technology and laboratory instrumentation advances in pharmaceutical research, focusing on the challenges and opportunities presented by big data, particularly in the context of drug discovery and development. Our speaker, Dan Ormsby, Director Science & Technology at Dotmatics will discuss the critical role of AI and machine learning in processing and deriving insights from massive datasets, emphasizing the importance of trustworthy, machine-ready data as a foundational element for successful AI adoption in Pharma R&D and the steps to get there.

Critically important premise to long term data management planning for all research infrastructures…

Thinking about deploying an LLM for use in pharma or biotech? Check out a webinar from our very own Swetabh Pathak on helpful considerations and useful tools 🤔 https://lnkd.in/eW2f4Gbt